DrugId:  1
1. Name:  Flavoxate
2. Groups:  Approved
3. Description:  A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
4. Indication:  For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
DrugId:  2
1. Name:  Fesoterodine
2. Groups:  Approved
3. Description:  Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
4. Indication:  For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DrugId:  3
1. Name:  Trospium
2. Groups:  Approved
3. Description:  Trospium is a urinary antispasmodic. It is sold under the brand name Sanctura in the US, and as Trosec in Canada. [Wikipedia]
4. Indication:  For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
DrugId:  4
1. Name:  Solifenacin
2. Groups:  Approved
3. Description:  Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
4. Indication:  For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DrugId:  5
1. Name:  Darifenacin
2. Groups:  Approved, Investigational
3. Description:  Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
4. Indication:  For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
DrugId:  6
1. Name:  AV608
2. Groups:  Investigational
3. Description:  AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
4. Indication:  Investigated for use/treatment in anxiety disorders, irritable bowel syndrome (IBS), and urinary incontinence.
DrugId:  7
1. Name:  Tolterodine
2. Groups:  Approved, Investigational
3. Description:  Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
4. Indication:  For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DrugId:  8
1. Name:  Oxybutynin
2. Groups:  Approved, Investigational
3. Description:  Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
4. Indication:  For the treatment of overactive bladder.
DrugId:  9
1. Name:  AZD0947
2. Groups:  Investigational
3. Description:  AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
4. Indication:  Intended for the treatment of urinary incontinence.
DrugId:  10
1. Name:  R450
2. Groups:  Investigational
3. Description:  R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
4. Indication:  Investigated for use/treatment in urinary incontinence.
DrugId:  11
1. Name:  Mirabegron
2. Groups:  Approved
3. Description:  Mirabegron is a beta-3 adrenergic receptor agonist for the management of overactive bladder. It is an alternative to antimuscarinic drugs for this indication. FDA approved on June 28, 2012.
4. Indication:  Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DrugId:  12
1. Name:  KW-7158
2. Groups:  Investigational
3. Description:  KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity (involuntary abnormal contraction of the bladder). The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion neurons.
4. Indication:  Investigated for use/treatment in urinary incontinence.
DrugId:  13
1. Name:  Propiverine
2. Groups:  Approved, Investigational
3. Description:  Propiverine has been investigated for the treatment of Overactive Bladder, Urinary Incontinence, Urinary Bladder, Overactive, and Overactive Bladder Syndrome.
4. Indication:  Not Available
DrugId:  14
1. Name:  BK-MDA
2. Groups:  Investigational
3. Description:  BK-MDA has been used in trials studying the treatment of Bladder Exstrophy and Urinary Incontinence.
4. Indication:  Not Available
DrugId:  15
1. Name:  DDP-200
2. Groups:  Investigational
3. Description:  DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
4. Indication:  Investigated for use/treatment in urinary incontinence.
DrugId:  16
1. Name:  Enobosarm
2. Groups:  Investigational
3. Description:  Enobosarm has been used in trials studying the treatment of Stress Urinary Incontinence and Triple Negative Breast Cancer.
4. Indication:  Not Available
DrugId:  17
1. Name:  OPC-51803
2. Groups:  Investigational
3. Description:  OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.
4. Indication:  Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence.
DrugId:  18
1. Name:  AP-1034
2. Groups:  Investigational
3. Description:  AP-1034 utilizes Antares Pharma's proprietary advanced transdermal delivery (ATD(TM)) gel technology designed to allow delivery of active substances across the skin. The oxybutynin formulation is a cosmetic quality, clear and odorless gel designed to be rapidly absorbed through the skin following once-a-day application on the abdomen, shoulders or thighs.
4. Indication:  Investigated for use/treatment in urinary incontinence.
DrugId:  19
1. Name:  Elocalcitol
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility.
DrugId:  20
1. Name:  Resiniferatoxin
2. Groups:  Investigational
3. Description:  Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission of physiological pain).
4. Indication:  Investigated for use/treatment in interstitial cystitis and urinary incontinence.
DrugId:  21
1. Name:  Casopitant
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in urinary incontinence and adverse effects (chemotherapy).
DrugId:  22
1. Name:  Duloxetine
2. Groups:  Approved
3. Description:  Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia.Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.
4. Indication:  For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.
DrugId:  23
1. Name:  Solabegron
2. Groups:  Investigational
3. Description:  Solabegron (GW-427,353) is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome.
4. Indication:  Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence.
DrugId:  24
1. Name:  Dicyclomine
2. Groups:  Approved
3. Description:  A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]
4. Indication:  For the treatment of functional bowel/irritable bowel syndromeincluding Colicky abdominal pain; diverticulitis
DrugId:  25
1. Name:  Propantheline
2. Groups:  Approved
3. Description:  A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. [PubChem]
4. Indication:  For the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.
